On Tuesday 6 December, the Emergency Task Force (ETF) of the European Medicines Agency (EMA) issued a statement in which it considers that bivalent messenger RNA vaccines adapted to both the BA.4 and BA.5 strains of SARS-CoV-2 and the original strain of the virus, which have so far been used for booster vaccination, can be used to complete a primary vaccination course.
The ETF reviewed laboratory studies and data indicating that the immune response to these adapted bivalent vaccines in...